In its second attempt to go public, biopharmaceutical firm Acorda Therapeutics priced 5.5 million shares at $6, well below its initially proposed $11-$13 range. The Hawthorne, NY based company, which markets and develops therapies to improve neurological function for multiple sclerosis sufferers and people with spinal cord injuries, first tried to go public in December 2003 but withdrew the offering in January 2004. Banc of America lead managed the IPO, and the stock is expected to begin trading on the Nasdaq on Friday.
